The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Commission and the pharmaceutical industry which aims to promote more efficient discovery and development of medicines by supporting research into the drug development process. The IMI is funded equally by the EU and industry and has a budget of EUR 2 billion for the period 2008-2017.
The second call for projects closed on 8 February 2010. We anticipate the third call in the autumn of 2010.
The following topics are anticipated to be reflected within the next call:
• Assessment of drug induced toxicity in relevant organs – surrogates for early drug failure
• Immunological safety of biopharmaceuticals
• Assessment inflammatory disease
• Improve the scientific and pre-clinical infrastructure for tuberculosis medicine
• Enhancing translation in neurological disease
• Development of personalized medicine approaches in diabetes
• Fostering a broader understanding of pharmaceutical R&D within the general public
The call will be published on this website as soon as it is available.
Further information
For more information on IMI please see the IMI website.